clinical stage life sciences venture capital investor

portfolio

amarathAmaranth Medical Inc. is developing a new generation of bioresorbable stents.

MEI-logoMEI Pharma is developing novel small molecule therapies for the treatment of cancer.

comentisCoMentis, Inc.is developing novel small molecule drugs for central nervous system diseases, including Alzheimer’s Disease, schizophrenia and other cognitive disorders.

enteroEnteroMedics, Inc. has developed a medical device that treats obesity through modulation of vagus nerve activity.

greatlakesGreat Lakes Pharmaceuticals, Inc. has developed an anti-microbial, anti-coagulant catheter lock solution for the prevention and treatment of catheter related blood stream infections (CRBSI).

healthfidelityHealth Fidelity, Inc. is developing and marketing a clinical natural language processing platform that automates the extraction of data from unstructured clinical text collected within healthcare organizations.

inviragenAcquired by Takeda in May, 2013. Inviragen, Inc. was developing vaccines to prevent infectious diseases which are prevalent in the the global market, including dengue. 

kereosKereos, Inc. is developing targeted chemotherapeutic drugs for the treatment of cancer. 

kfxKFx Medical Corporation has developed a novel product to aid the surgical attachment of biceps tendons and anterior cruciate ligaments to bone as well as novel intellectual property for the surgical repair of rotator cuff injuries. 

midMinimally Invasive Devices, Inc. has developed the FloShield family of products which are unmatched in keeping the laproscopic or robotic lens free of debris and fog in minimally invasive surgery procedures. 

mirabilisMirabilis Medica, Inc. has developed a HIFU-based system for the ablation of uterine fibroids.

revascularAcquired by Boston Scientific Corporation in February, 2011. Revascular Therapeutics, Inc. had developed a medical device system for treatment of total occlusions in the peripheral arteries.

visioneeringVisioneering Technologies, Inc. has developed a next generation contact lens for the correction of presbyopia (age related reduction in near vision).

xlumenaAcquired by Boston Scientific Corporation in April, 2015. XLumena, Inc. has developed medical device products that enable minimally invasive endoscopic surgical interventions to treat diseases of the digestive system, including pancreatic and biliary diseases.